Category

Daily Briefs

Daily Brief China: Binjiang Service Group, Pony AI, Anxin Trust Co Ltd A, Zuoli Kechuang Micro Finance and more

By | China, Daily Briefs

In today’s briefing:

  • Primer: Binjiang Service Group (3316 HK) – Nov 2025
  • Weekly Deals Digest (02 Nov) – Pony AI, Seres, WeRide, ANE, Mayne, Brainpad, SCSK, Sumitomo Riko
  • Primer: Anxin Trust Co Ltd A (600816 CH) – Nov 2025
  • Primer: Zuoli Kechuang Micro Finance (6866 HK) – Nov 2025


Primer: Binjiang Service Group (3316 HK) – Nov 2025

By αSK

  • Binjiang Service is a high-growth property management firm with a strong brand in the premium segment of the Yangtze River Delta, benefiting from the stable pipeline of its reputable parent developer, Binjiang Real Estate.
  • The company is strategically shifting its focus towards high-margin ‘5S’ value-added services (VAS), particularly in soft decoration and community living, to offset declining revenues and margins in its non-owner VAS segment.
  • While demonstrating robust top-line growth and a generous dividend policy, the company faces significant risks from the broader downturn in China’s property market, intense industry competition, and rising operational costs.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Weekly Deals Digest (02 Nov) – Pony AI, Seres, WeRide, ANE, Mayne, Brainpad, SCSK, Sumitomo Riko

By Arun George


Primer: Anxin Trust Co Ltd A (600816 CH) – Nov 2025

By αSK

  • Anxin Trust is in a precarious recovery phase following a state-backed bailout in 2021, which was necessitated by a severe debt crisis stemming from mismanagement and misappropriation of funds.
  • The company has returned to profitability in the last two years after significant losses, but its financial performance remains volatile, and it faces extremely high valuation multiples, suggesting the market has priced in a full, but uncertain, recovery.
  • The outlook is heavily dependent on the successful execution of its new strategy under a revamped, state-influenced management team and navigating China’s increasingly stringent regulatory environment for the trust industry.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Zuoli Kechuang Micro Finance (6866 HK) – Nov 2025

By αSK

  • Zuoli Kechuang Micro Finance is a licensed microfinance company based in Zhejiang Province, China, facing significant headwinds as evidenced by a consistent decline in revenue and net income over the past several years.
  • The company’s stock trades at a deeply discounted valuation, with a Price-to-Book ratio significantly below 1.0x, which may attract value-oriented investors. This is supported by a high Smartscore for Value (5/5).
  • Despite a historically attractive dividend, the payout has been decreasing steadily, reflecting the underlying pressure on earnings and cash flow. The 3-year CAGR for dividends is sharply negative at -38.10%.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Nidec Corp, Japan Data Science Consortium, Advantest Corp, Elan Corp, Scsk Corp and more

By | Daily Briefs, Japan

In today’s briefing:

  • Last Week In Event SPACE: Nidec/Ibiden, LG Chem, Mayne Pharma, Jardine Matheson
  • Primer: Japan Data Science Consortium (4418 JP) – Nov 2025
  • Whirlwind Japan EOM October for Stocks, Advantest, Nidec, BoJ, Gold, and the Rest
  • Primer: Elan Corp (6099 JP) – Nov 2025
  • Mostly) Asia-Pac M&A: SCSK Corp, AUB, Brainpad, ANE Cayman, Sumitomo Densetsu, Sumitomo Densetsu


Last Week In Event SPACE: Nidec/Ibiden, LG Chem, Mayne Pharma, Jardine Matheson

By David Blennerhassett

  • Nidec (6594 JP)‘s deletion is a LOT of stock to sell. The Ibiden (4062 JP)‘s Nikkei 225 inclusion is huge. It’ll make the stock enormously squeezy for a long while.
  • Palliser has a point. LG Chem (051910 KS) should pare down its LG Energy Solution (373220 KS) stake, and buy back shares. Yet, would/will management stubbornly swat away any such proposal?
  • The latest twist in the Mayne Pharma (MYX AU) saga as FIRB looks set to ding the transaction if there is a possibility Cosette closes a manufacturing site in Adelaide.

Primer: Japan Data Science Consortium (4418 JP) – Nov 2025

By αSK

  • Explosive revenue growth driven by Japan’s accelerating digital transformation and AI adoption, positioning JDSC as a key player in a burgeoning market.
  • Recent pivot to profitability in FY2025 after a period of heavy investment highlights scaling potential, though earnings have been volatile.
  • A unique business model leveraging partnerships with industry leaders and academic ties with the University of Tokyo to co-develop and deploy AI solutions, creating a potential competitive advantage.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Whirlwind Japan EOM October for Stocks, Advantest, Nidec, BoJ, Gold, and the Rest

By Jay Cameron

  • Japanese markets saw Advantest and Nintendo poised for growth, with strategic moves impacting their stock performance.
  • The Bank of Japan maintained its policy, influencing the JGB curve and broader market.
  • Gold’s favorable environment, driven by global monetary shifts, presents options market opportunities.

Primer: Elan Corp (6099 JP) – Nov 2025

By αSK

  • Elan Corp is a market leader in Japan’s growing nursing care support sector, capitalizing on the nation’s super-aged society. Its core business provides rental and laundry services for clothing, towels, and daily necessities to hospital patients and nursing home residents, creating a convenient, all-in-one solution.
  • The company has demonstrated a strong and consistent track record of top-line growth, with revenue increasing for 17 consecutive years. This is driven by an expanding network of contracted healthcare facilities and the powerful demographic tailwind of Japan’s aging population.
  • Despite robust operational growth, the company’s stock has de-rated from its pandemic-era highs. While revenue and cash flow remain strong, recent financial data indicates pressure on profit margins, a key area for investor monitoring. The valuation now appears more reasonable compared to historical levels and some international peers.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.



💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: Overview#39 – Uranium’s Surge and more

By | Daily Briefs, Macro

In today’s briefing:

  • Overview#39 – Uranium’s Surge, Gold’s Lull, and Some Geopolitics in Between


Overview#39 – Uranium’s Surge, Gold’s Lull, and Some Geopolitics in Between

By Rikki Malik

  • A review of recent events/data impacting our investment themes and outlook
  • Uranium takes centre stage, while precious metals remain in a corrective phase
  • Xi and Trump finally have their sit-down – important details behind the headlines

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: ICICI Bank Ltd, Dian Swastatika Sentosa, Chroma Ate Inc, Groww, Bio-Thera Solutions Ltd, Softcare, LG Chem Ltd, Binjiang Service Group, Nidec Corp and more

By | Daily Briefs, Most Read

In today’s briefing:

  • NIFTY Bank Index: Methodology Changes to Result in Big Flows
  • IDX30/​​LQ45/IDX80 Index Rebalance: Plenty of Change with 4 Days to Trade
  • Chroma Ate (2360 TT): Double Index Inclusion Coming Up with Plenty to Buy
  • Groww IPO: Growwing Fast; Index Inclusions Will Be Sloww; Small Floww
  • Quiddity Leaderboard STAR 50/100 Dec25: Final Expectations; New Ideas
  • Softcare Pre-IPO: Decent Cornerstones, Riding on Africa Growth
  • LG Chem: Considering Higher Dividend Payout Using Sale Proceeds from LGES
  • Primer: Binjiang Service Group (3316 HK) – Nov 2025
  • STAR50 Index Earning Revision (Oct): SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR
  • Last Week In Event SPACE: Nidec/Ibiden, LG Chem, Mayne Pharma, Jardine Matheson


NIFTY Bank Index: Methodology Changes to Result in Big Flows

By Brian Freitas

  • In May, SEBI recommended changes to the minimum number of constituents for non-benchmark indices and the capping for those indices. Then came the market consultation in August.
  • SEBI has now confirmed the changes along with the timeline for capping changes to the largest stocks in the index.
  • The changes could commence in December and continue till March. The adds will take place in December and weight changes for the largest stocks will take place in 4 tranches.

IDX30/​​LQ45/IDX80 Index Rebalance: Plenty of Change with 4 Days to Trade

By Brian Freitas


Chroma Ate (2360 TT): Double Index Inclusion Coming Up with Plenty to Buy

By Brian Freitas

  • A massive rally in Chroma Ate Inc (2360 TT) should see the stock added to a global index in November and then to another country ETF in December.
  • With one exception, Chroma Ate Inc (2360 TT) has outperformed its peers over the last 6 months. With large buying to come, that could continue in the short-term.
  • There is positioning in Chroma Ate Inc (2360 TT) and its peers. With continued momentum in the stock, the path of least resistance is higher.

Groww IPO: Growwing Fast; Index Inclusions Will Be Sloww; Small Floww

By Brian Freitas

  • Groww (1573648D IN) is looking to list on the exchanges by selling 663.23m shares via a primary and secondary offering to raise US$752m at a valuation of US$7bn.
  • The price band has been set at INR 95-100/share, and the issue is likely to price at the top end of the range.
  • The stock will not get Fast Entry to global indices. Inclusion at regular rebalances will commence in June 2026 but flow will be small given the low float.

Quiddity Leaderboard STAR 50/100 Dec25: Final Expectations; New Ideas

By Janaghan Jeyakumar, CFA

  • STAR 50 Index is a tech-focused, blue-chip index in Mainland China which tracks the top 50 largest and most liquid names in the STAR market of the Shanghai Stock Exchange.
  • STAR 100 index tracks the next 100 names (51st-150th ranks) and it represents the mid-cap segment of the STAR market.
  • In this insight, we have presented our final expectations for ADDs and DELs for the upcoming December 2025 index rebal event.

Softcare Pre-IPO: Decent Cornerstones, Riding on Africa Growth

By Nicholas Tan

  • Softcare (SOFT HK) is looking to raise up to US$307m in its upcoming Hong Kong IPO.
  • It is an international hygiene product corporation with a focus on fast-growing Emerging Markets including Africa, Latin America and Central Asia. 
  • In this note, we examine the IPO dynamics, and look at the firm’s valuation.

LG Chem: Considering Higher Dividend Payout Using Sale Proceeds from LGES

By Douglas Kim

  • LG Chem is considering on paying higher dividends using sale proceeds from LG Energy Solution. 
  • This breaks the company’s principle of using only ordinary income from operating activities as a source for dividends.
  • If indeed LG Chem goes ahead with this plan, this would be as a result of heightened demands from major activist investors including Palliser Capital.

Primer: Binjiang Service Group (3316 HK) – Nov 2025

By αSK

  • Binjiang Service is a high-growth property management firm with a strong brand in the premium segment of the Yangtze River Delta, benefiting from the stable pipeline of its reputable parent developer, Binjiang Real Estate.
  • The company is strategically shifting its focus towards high-margin ‘5S’ value-added services (VAS), particularly in soft decoration and community living, to offset declining revenues and margins in its non-owner VAS segment.
  • While demonstrating robust top-line growth and a generous dividend policy, the company faces significant risks from the broader downturn in China’s property market, intense industry competition, and rising operational costs.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


STAR50 Index Earning Revision (Oct): SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR

By Ke Yan, CFA, FRM

  • We analysed the earning revision of component stocks of STAR50 in the past month.
  • We tabulated stocks with the top impact on index’s EPS, stocks’ EPS revision, and revenue revision.
  • We highlighted EPS revision on SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR, CAMBRICON TECHNOLOGIES, Trina Solar, Shengyi Electronics, Cambricon Technologies, Transsion, Supcon Technology.

Last Week In Event SPACE: Nidec/Ibiden, LG Chem, Mayne Pharma, Jardine Matheson

By David Blennerhassett

  • Nidec (6594 JP)‘s deletion is a LOT of stock to sell. The Ibiden (4062 JP)‘s Nikkei 225 inclusion is huge. It’ll make the stock enormously squeezy for a long while.
  • Palliser has a point. LG Chem (051910 KS) should pare down its LG Energy Solution (373220 KS) stake, and buy back shares. Yet, would/will management stubbornly swat away any such proposal?
  • The latest twist in the Mayne Pharma (MYX AU) saga as FIRB looks set to ding the transaction if there is a possibility Cosette closes a manufacturing site in Adelaide.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Top 10 Highlights from the APAC PE, VC and Startup Ecosystem this Week – 02 Nov 2025

By | Private Markets, Smartkarma Newswire

Top ten highlights from the APAC PE, VC, and startup ecosystem this week:

  1. Indian Startup Fundraising Slows Down: Fundraising by Indian startups hit a new low in Q3 2025, with private equity and venture capital investments dropping to $3 billion.
  2. Greater China Startup Funding Surges: Startups in Greater China raised nearly $3.6 billion in September, marking a 36.5% increase in deal value compared to August.
  3. Earnings Highlights: Indonesia’s GoTo Group and Bukalapak reported improved financial performance, while Swiggy in India saw a narrower second-quarter loss.
  4. Stockbit Pte Ltd’s Profitability Boost: The Singapore holding company for Stockbit and Bibit trimmed its net loss in 2023 due to higher revenue and reduced marketing expenses.
  5. Investment Updates: Temasek is in talks to invest in Somerset Indus Capital Partners’ third fund, KV Asia Capital is finalising its third private equity fund, and Lighthouse Canton plans to invest over $1.5 billion in India.
  6. Deal News: Notable deals include Kopi Kenangan’s backers selling stake, layoffs at Blibli and Paper.id, and ObvioHealth raising capital from existing and new investors.
  7. Funding Rounds: Various startups secured funding, such as Moladin raising around $35 million and Optimo Capital raising Rs 150 crore in a Series A round.
  8. Global Investments: Ant International’s strategic investment in R2, FundPark’s $71 million raise, and Prosus and Accel’s $1 million investments in startups.
  9. Technology Advances: JBD’s $140.4 million funding round, VoidZero’s $12.5 million in Series A round, and 2C2P’s rebrand and $60 million investment plan.
  10. Industry Insights: Snapmint’s fresh funding, Deep dives into renewable energy cost-competitiveness and Sea Limited’s investor attention shift.

APAC Private Markets Research

Explore latest Insights on APAC Private Markets on Smartkarma


Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Also, check out the latest in ECM Research on Smartkarma